reports
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Resu...
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a ...
NextNav Announces Date for First Quarter 2024 Earnings Call
NextNav Announces Date for First Quarter 2024 Earnings Call MCLEAN, Va., April 24, 2024 (GLOBE NEWSWIRE) -- NextNav (Nasdaq: NN), a leader in next generation positioning, navigation, timing (PNT) and 3D geolocation, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the market closes on Wednesday, May 8, 2024, and will host a conference call the same day at 5:00 PM ET to discuss its results. Registration for the conference call can be completed by visiting the following website prior to, or on the day of, the conference call: . ...
Orion Group Holdings Reports First Quarter 2024 Results
Orion Group Holdings Reports First Quarter 2024 Results HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today reported its financial results for the first quarter ended March 31, 2024. Highlights for the quarter ended March 31, 2024: Contract revenues of $160.7 millionGAAP net loss was $6.1 million or $0.19 per diluted shareAdjusted net loss was $4.0 million or $0.12 per diluted shareAdjusted EBITDA was $4.1 millionBacklog and contracts awarded subsequent to quarter end totaled $857 million S...
TScan Therapeutics Announces Upcoming Presentations at the 2024 Americ...
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtu...
Brookline Bancorp Announces First Quarter Results
Brookline Bancorp Announces First Quarter Results Net Income of $14.7 million, EPS of $0.16 Quarterly Dividend of $0.135 BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Brookline Bancorp, Inc. (NASDAQ: BRKL) (the “Company”) today announced net income of $14.7 million, or $0.16 per basic and diluted share, for the first quarter of 2024, compared to net income of $22.9 million, or $0.26 per basic and diluted share, for the fourth quarter of 2023, and net income of $7.6 million, or $0.09 per basic and diluted share, for the first quarter of 2023. Paul Perrault, Chairman and CEO, commented on t...
Amplify Energy Schedules First Quarter 2024 Earnings Release and Confe...
Amplify Energy Schedules First Quarter 2024 Earnings Release and Conference Call HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (“Amplify” or the “Company”) (NYSE: AMPY) announced today that it will report first quarter 2024 financial and operating results after the U.S. financial markets close on May 8, 2024. Management will host a conference call at 10:00 a.m. CT on May 9, 2024 to discuss the Company’s results. Interested parties are invited to participate in the conference call by dialing (800) 901-2707 (Conference ID: AEC1Q24) at least 15 minutes prior to the start o...
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, develop...
Ethan Allen Reports Fiscal 2024 Third Quarter Results Highlighted by R...
Ethan Allen Reports Fiscal 2024 Third Quarter Results Highlighted by Robust Balance Sheet, Strong Cash Dividends and Double-Digit Operating Margin; Lower Demand Reflects Post Pandemic Period DANBURY, CT, April 24, 2024 (GLOBE NEWSWIRE) -- Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD), a leading interior design destination, today reported its financial and operating results for the fiscal 2024 third quarter ended March 31, 2024. Farooq Kathwari, Ethan Allen’s Chairman, President and CEO commented, “We are pleased with our financial performance and the continu...
Mama’s Creations Reports Fourth Quarter and Fiscal Year 2024 Financial...
Mama’s Creations Reports Fourth Quarter and Fiscal Year 2024 Financial Results “Catapult” in 4 Cs Strategy Drives 17% Revenue Growth and $6.7 Million in Cash Flow from Operations in Fourth Quarter EAST RUTHERFORD, NJ, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, has reported its financial results for fourth quarter and fiscal year ended January 31, 2024. Financial Summary: Three Months Ended Jan. 31, Fiscal Year Ended Jan. 31, $ in millions 2024 2023 % Increase 2024 2023 % Increase Revenu...
Eagle Bancorp, Inc. Announces Results of Operations for First Quarter ...
Eagle Bancorp, Inc. Announces Results of Operations for First Quarter 2024 BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Eagle Bancorp, Inc. (the "Company") (NASDAQ: EGBN), the parent company of EagleBank (the "Bank"), today announced a net loss of $338 thousand for the first quarter 2024, compared to net income of $20.2 million for the fourth quarter 2023 (the "prior quarter"). Net loss was $(0.01) per share (diluted) for the first quarter 2024, compared to net income of $0.67 per share (diluted) for the prior quarter. Pre-provision net revenue ("PPNR")1, a non-GAAP financial measure...
Cidara Therapeutics Reacquires Global Development and Commercial Right...
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET ...
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at...
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conju...
Covenant Logistics Group Announces First Quarter Financial and Operati...
Covenant Logistics Group Announces First Quarter Financial and Operating Results CHATTANOOGA, Tenn., April 24, 2024 (GLOBE NEWSWIRE) -- Covenant Logistics Group, Inc. (NASDAQ/GS: CVLG) (“Covenant” or the “Company”) announced today financial and operating results for the first quarter ended March 31, 2024. The Company’s conference call to discuss the quarter will be held at 10:00 A.M. Eastern Time on Thursday, April 25, 2024. Chairman and Chief Executive Officer, David R. Parker, commented: “We are pleased to report first quarter earnings of $0.29 per diluted share and non-GAAP adju...
Essential Properties Announces First Quarter 2024 Results
PRINCETON, N.J.--(BUSINESS WIRE)-- Essential Properties Realty Trust, Inc. (NYSE: EPRT; “Essential Properties” or the “Company”) today announced operating results for the three months ended March 31, 2024. First Quarter 2024 Financial and Operating Highlights: Operating Results (compared to First Quarter 2023): • Investments (79 properties) $ Invested $248.8 million Weighted Avg Cash Cap Rate 8.1% • Dispositions (7 properties) Net Proceeds $11.9 million Weighted Avg Cash Cap Rate 6.5% ...
Appian To Announce First Quarter 2024 Financial Results on May 2
Appian To Announce First Quarter 2024 Financial Results on May 2 MCLEAN, Va., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APPN) today announced that it will release financial results for the first quarter ended March 31, 2024, before the U.S. financial markets open on Thursday, May 2, 2024. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, participants can dial in the same way they alway...
Beyond Meat® to Report First Quarter 2024 Financial Results on May 8, ...
Beyond Meat® to Report First Quarter 2024 Financial Results on May 8, 2024 EL SEGUNDO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ: BYND) (“Beyond Meat” or “the Company”), a leader in plant-based meat, announced today it will report financial results for the first quarter 2024 ended March 30, 2024 on Wednesday, May 8, 2024 after market close. The Company will host a conference call to discuss these results at 5:00 p.m. Eastern, 2:00 p.m. Pacific. Investors interested in participating in the live call can dial 412-902-4255. There will also be a simultaneous, live...
AMERISAFE Announces 2024 First Quarter Results
DERIDDER, La.--(BUSINESS WIRE)-- AMERISAFE, Inc. (Nasdaq: AMSF), a specialty provider of workers’ compensation insurance focused on high-hazard industries, today announced results for the first quarter ended March 31, 2024. Three Months Ended March 31, 2024 2023 % Change (in thousands, except per share data) Net premiums earned $ 68,446 $ 69,181 -1.1 % Net investment income 7,366 7,433 -0.9 % ...
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00...
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual ...
Predictive Oncology Announces Abstract Accepted for Presentation at th...
Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting PITTSBURGH, April 24, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il. The abstract highlights results from a recent study that Predictive Oncology completed in collaboration with UPMC Magee...
Venus Concept Announces Loan Purchase and Completion of First Phase of...
Venus Concept Announces Loan Purchase and Completion of First Phase of Refinancing MSLP Loan Purchase and Short-term Bridge Financing of Up To $5.0 million By Madryn Asset Management TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that on April 23, 2024, its existing Main Street Lending Program Loan (“MSLP Loan”) was purchased by affiliates of Madryn Asset Management, LP (“Madryn”) for an undisclosed amount from the City National Bank of Florida (“CNB”) with th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.